Is Zimmer Biomet Holdings, Inc. (ZBH) Overvalued?
We dive into why Zimmer Biomet Holdings, Inc. (ZBH) could be considered overvalued on 2026-07-21, based on AAII’s Value Score and Grade.Jenna Brashear
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
Michael Rose
| Share Statistics | ZBH | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $18,371.2 | $334.8 | 85% |
|
| Shares Out (Mil) | 195.8 | 41.7 | 76% |
|
| Institutional Ownership | 99.8% | 77.3% | 94% |
|
| Float (Mil) | 192.9 | 34.7 | 74% |
|
| Beta | 0.47 | 0.86 | 26% |
|
| Avg Daily Volume (000s) | 2,175 | 266 | 84% |
|
| Price Change (52-week) |
0.0% | 60.7% | 46% |
|
| Growth | ZBH | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.1% | 11.8% | 41% |
|
| Net Income (5yr) | 47.9% | (5.8%) | 93% |
|
| EPS (5yr) | 48.8% | 10.7% | 92 |
|
| Dividends (5yr) | 0.0% | 0.0% | 78% |
|
| Cash Flow (5yr) | (17.5%) | (16.1%) | 40% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 24 | 27 | 27 | |
| Current EPS | $2.010 | $8.472 | $9.003 | |
| Month Ago EPS | $2.012 | $8.478 | $8.990 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 0 | |
| Three Months Ago EPS | $2.012 | $8.472 | $8.993 | |
| Year/Year Chg | 64.8% | 138.6% | 170.9% | |
| Financials | ZBH | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $8,409 | $152 | 82% |
|
| Net Income (TTM) (Mil) | $761 | ($11) | 84% |
|
| EPS (TTM) | $3.863 | ($0.500) | 83% |
|
| Operating Cash Flow (TTM) (Mil) | $1,674 | ($2) | 86% |
|
| Net Cash Flow (TTM) (Mil) | ($961) | $1 | 4% |
|
| Long-Term Debt (Q1) (Mil) | $6,411 | $22 | 88% |
|
| Enterprise Value (Q1) (Mil) | $23,557 | $304 | 85% |
|
| Valuation | ZBH | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.45 | 2.88 | 38% |
|
| P/E | 24.6 | 30.5 | 60% |
|
| Dividend Yield | 1.0% | 0.0% | 67% |
|
| PEG (5yr hist) | 0.2 | 1.9 | 7% |
|
| Ratios | ZBH | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 70.2% | 59.1% | 81% |
|
| Net Margin | 9.1% | (7.7%) | 61% |
|
| ROA | 3.4% | (13.7%) | 64% |
|
| ROE | 6.1% | (15.9%) | 47% |
|
| Liabilities to Assets | 44.2% | 44.9% | 35% |
|
| F-Score | 6 | 4 | 69% |
|
Zimmer Biomet Holdings, Inc. did not pass any screens on 7/30/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors